Cardiovascular Regenerative Patches
Pericardial Closure/Reconstruction
Key Facts
About CorVivo
CorVivo is a clinical-stage biotech company pioneering a regenerative medicine platform for cardiovascular applications. Its core technology is a proprietary extracellular matrix (ECM)-derived biomaterial that acts as a scaffold to facilitate the body's own repair processes for heart and vascular tissue. The company appears to be in the clinical development phase, targeting significant unmet needs in cardiac surgery and structural heart disease. As a private entity, it is likely funded by venture capital and is building its clinical and commercial strategy.
View full company profileAbout CorVivo
CorVivo is a clinical-stage biotech company pioneering a regenerative medicine platform for cardiovascular applications. Its core technology is a proprietary extracellular matrix (ECM)-derived biomaterial that acts as a scaffold to facilitate the body's own repair processes for heart and vascular tissue. The company appears to be in the clinical development phase, targeting significant unmet needs in cardiac surgery and structural heart disease. As a private entity, it is likely funded by venture capital and is building its clinical and commercial strategy.
View full company profileAbout CorVivo
CorVivo is a clinical-stage biotech company pioneering a regenerative medicine platform for cardiovascular applications. Its core technology is a proprietary extracellular matrix (ECM)-derived biomaterial that acts as a scaffold to facilitate the body's own repair processes for heart and vascular tissue. The company appears to be in the clinical development phase, targeting significant unmet needs in cardiac surgery and structural heart disease. As a private entity, it is likely funded by venture capital and is building its clinical and commercial strategy.
View full company profile